112 related articles for article (PubMed ID: 10560804)
1. Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes.
Frank RD; Farber H; Stefanidis I; Lanzmich R; Kierdorf HP
Kidney Int Suppl; 1999 Nov; (72):S41-5. PubMed ID: 10560804
[TBL] [Abstract][Full Text] [Related]
2. In vitro studies on hirudin elimination by haemofiltration: comparison of three high-flux membranes.
Frank RD; Farber H; Lanzmich R; Floege J; Kierdorf HP
Nephrol Dial Transplant; 2002 Nov; 17(11):1957-63. PubMed ID: 12401853
[TBL] [Abstract][Full Text] [Related]
3. Hemofiltration of recombinant hirudin by different hemodialyzer membranes: implications for clinical use.
Benz K; Nauck MA; Böhler J; Fischer KG
Clin J Am Soc Nephrol; 2007 May; 2(3):470-6. PubMed ID: 17699453
[TBL] [Abstract][Full Text] [Related]
4. Removal of lepirudin, a recombinant hirudin, by hemodialysis, hemofiltration, or plasmapheresis.
Willey ML; de Denus S; Spinler SA
Pharmacotherapy; 2002 Apr; 22(4):492-9. PubMed ID: 11939684
[TBL] [Abstract][Full Text] [Related]
5. Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems.
Koster A; Merkle F; Hansen R; Loebe M; Kuppe H; Hetzer R; Crystal GJ; Mertzlufft F
Anesth Analg; 2000 Aug; 91(2):265-9. PubMed ID: 10910829
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hirudin overdosage in a dialysis patient with heparin-induced thrombocytopenia with mixed hemodialysis and hemofiltration treatment.
Mon C; Moreno G; Ortiz M; Diaz R; Herrero JC; Oliet A; Rodriguez I; Ortega O; Gallar P; Vigil A
Clin Nephrol; 2006 Oct; 66(4):302-5. PubMed ID: 17063999
[TBL] [Abstract][Full Text] [Related]
7. In vitro study of r-hirudin permeability through membranes of different haemodialysers.
Bucha E; Kreml R; Nowak G
Nephrol Dial Transplant; 1999 Dec; 14(12):2922-6. PubMed ID: 10570098
[TBL] [Abstract][Full Text] [Related]
8. Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies.
Liebe V; Brückmann M; Fischer KG; Haase KK; Borggrefe M; Huhle G
Semin Thromb Hemost; 2002 Oct; 28(5):483-90. PubMed ID: 12420244
[TBL] [Abstract][Full Text] [Related]
9. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis.
Fischer KG; van de Loo A; Böhler J
Kidney Int Suppl; 1999 Nov; (72):S46-50. PubMed ID: 10560805
[TBL] [Abstract][Full Text] [Related]
10. Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin.
Fischer KG; Liebe V; Hudek R; Piazolo L; Haase KK; Borggrefe M; Huhle G
Thromb Haemost; 2003 Jun; 89(6):973-82. PubMed ID: 12783109
[TBL] [Abstract][Full Text] [Related]
11. Hirudin determination in plasma can be strongly influenced by the prothrombin level.
Lindhoff-Last E; Piechottka GP; Rabe F; Bauersachs R
Thromb Res; 2000 Oct; 100(1):55-60. PubMed ID: 11053617
[TBL] [Abstract][Full Text] [Related]
12. Hirudin in renal insufficiency.
Fischer KG
Semin Thromb Hemost; 2002 Oct; 28(5):467-82. PubMed ID: 12420243
[TBL] [Abstract][Full Text] [Related]
13. Hirudin in heparin-induced thrombocytopenia.
Lubenow N; Greinacher A
Semin Thromb Hemost; 2002 Oct; 28(5):431-8. PubMed ID: 12420238
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics study of recombinant hirudin in the plasma of rats using chromogenic substrate, ELISA, and radioisotope assays.
Jiang SY; Jiao J; Zhang TT; Xu YP
PLoS One; 2013; 8(6):e64336. PubMed ID: 23785400
[TBL] [Abstract][Full Text] [Related]
15. A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II : adaptation of the ecarin clotting time to the act II device.
Koster A; Loebe M; Hansen R; Bauer M; Mertzlufft F; Kuppe H; Hetzer R
J Thorac Cardiovasc Surg; 2000 Jun; 119(6):1278-83. PubMed ID: 10838548
[TBL] [Abstract][Full Text] [Related]
16. Bleeding after intermittent or continuous r-hirudin during CVVH.
Kern H; Ziemer S; Kox WJ
Intensive Care Med; 1999 Nov; 25(11):1311-4. PubMed ID: 10654220
[TBL] [Abstract][Full Text] [Related]
17. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
18. Modified plasma-based ecarin clotting time assay for monitoring of recombinant hirudin during cardiac surgery.
Choi TS; Khan AI; Greilich PE; Kroll MH
Am J Clin Pathol; 2006 Feb; 125(2):290-5. PubMed ID: 16393689
[TBL] [Abstract][Full Text] [Related]
19. Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis.
Matzke GR; Frye RF; Joy MS; Palevsky PM
Pharmacotherapy; 2000 Jun; 20(6):635-43. PubMed ID: 10853618
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic studies with recombinant hirudin in dogs.
Nowak G; Markwardt F; Fink E
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):70-4. PubMed ID: 2459035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
